Procyanidin C1 inhibits bleomycin‐induced pulmonary fibrosis in mice by selective clearance of senescent myofibroblasts
The FASEB Journal · 2024
DOI: 10.1096/fj.202302547rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Min Shao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Xiangya School of Medicine, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Bleomycin, Myofibroblasts, Pulmonary Fibrosis, Cellular Senescence. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China (NSFC), Natural Science Foundation of Hunan Province, Natural Science Foundation of Changsha.
Abstract (Originalsprache)
Pulmonary fibrosis is a formidable challenge in chronic and age‐related lung diseases. Myofibroblasts secrete large amounts of extracellular matrix and induce pro‐repair responses during normal wound healing. Successful tissue repair results in termination of myofibroblast activity via apoptosis; however, some myofibroblasts exhibit a senescent phenotype and escape apoptosis, causing over‐repair that is characterized by pathological fibrotic scarring. Therefore, the removal of senescent myofibroblasts using senolytics is an important method for the treatment of pulmonary fibrosis. Procyanidin C1 (PCC1) has recently been discovered as a senolytic compound with very low toxicity and few side effects. This study aimed to determine whether PCC1 could improve lung fibrosis by promoting apoptosis in senescent myofibroblasts and to investigate the mechanisms involved. The results showed that PCC1 attenuates bleomycin (BLM)‐induced pulmonary fibrosis in mice. In addition, we found that PCC1 inhibited extracellular matrix deposition and promoted the apoptosis of senescent myofibroblasts by increasing PUMA expression and activating the BAX signaling pathway. Our findings represent a new method of pulmonary fibrosis management and emphasize the potential of PCC1 as a senotherapeutic agent for the treatment of pulmonary fibrosis, providing hope for patients with pulmonary fibrosis worldwide. Our results advance our understanding of age‐related diseases and highlight the importance of addressing cellular senescence in treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Xiangya School of Medicine, Central South University, Changsha, China.
- Department of Community Nursing, Xiangya Nursing School, Central South University, Changsha, China.
- Hunan Key Laboratory of Organ Fibrosis, Changsha, China.
ORCID-Profile: Ziqiang Luo, Yan Zhou
Förderung
- National Natural Science Foundation of China (NSFC)
- Natural Science Foundation of Hunan Province
- Natural Science Foundation of Changsha
Zitieren
APA
Shao, M., Qiu, Y., Shen, M., Liu, W., Feng, D., Luo, Z., & Zhou, Y. (2024). Procyanidin C1 inhibits bleomycin‐induced pulmonary fibrosis in mice by selective clearance of senescent myofibroblasts. The FASEB Journal. https://doi.org/10.1096/fj.202302547rr
Vancouver
Shao M, Qiu Y, Shen M, Liu W, Feng D, Luo Z, et al. Procyanidin C1 inhibits bleomycin‐induced pulmonary fibrosis in mice by selective clearance of senescent myofibroblasts. The FASEB Journal. 2024. doi:10.1096/fj.202302547rr
BibTeX
@article{Shao2024,
author = {Shao, Min and Qiu, Yujia and Shen, Mengxia and Liu, Wei and Feng, Dandan and Luo, Ziqiang and Zhou, Yan},
title = {Procyanidin C1 inhibits bleomycin‐induced pulmonary fibrosis in mice by selective clearance of senescent myofibroblasts},
journal = {The FASEB Journal},
year = {2024},
doi = {10.1096/fj.202302547rr}
}
EUVIMED